209
Participants
Start Date
November 18, 2014
Primary Completion Date
March 15, 2017
Study Completion Date
March 15, 2017
Tofacitinib
tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
Tofacitinib
tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
Tohoku University Hospital/ Department of Hematology and Rheumatology, Sendai
Japanese Red Cross Nagoya Daiichi Hospital, Nagoya
National Hospital Organization Nagoya Medical Center, Nagoya
National Hospital Organization Toyohashi Medical Center, Toyohashi
Yamada Rheumatology Clinic, Matsuyama
St. Mary's Hospital, Kurume
Gunma Rheumatism Clinic, Takasaki-shi
Inoue Hospital, Tohrimachi, Takasaki
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima
National Hospital Organization Asahikawa Medical Center, Asahikawa
Katayama Orthopaedic Rheumatology Clinic, Asahikawa
Yoshida orthopaedics and rheumatologyclinic, Morioka
Komagamine Rheumatoid Orthopaedic Clinic, Morioka
National Hospital Organization Sagamihara National Hospital, Sagamihara
National Hospital Organization Yokohama Medical Center, Yokohama
Osaki Citizen Hospital, Oosaki
Nagano Red Cross Hospital, Nagano
Sasebo Chuo Hospital, Sasebo
National Hospital Organization Ureshino Medical Center, Ureshino-shi
Soshigayaokura clinic, Setagaya-ku
Showa University Hospital, Shinagawa-ku
Honjo Rheumatism Clinic, Takaoka-shi
Miyasato Clinic, Shūnan
National Hospital Organization Chiba-East Hospital, Chiba
Sugimoto rheumatology and internal medicine clinic, Fukui
National Hospital Organization Kyushu Medical Center, Fukuoka
SHONO Rheumatism Clinic, Fukuoka
Sagawa Akira Rheumatology Clinic, Hokkaido
Matsubara Mayflower Hospital, Hyōgo
Yokohama Minami Kyosai Hospital, Kanagawa
Kumamoto Orthopaedic Hospital, Kumamoto
Japanese Red Cross Kyoto Daiichi Hospital, Kyoto
Oribe Clinic of Rheumatology and Internal Medicine, Ōita
Otsuka Clinic of Rheumatism and Medicine, Ōita
Rabbit Clinic, Saitama
Hirose Clinic, Saitama
Lead Sponsor
Pfizer
INDUSTRY